Business Context and Reporting Period
This Form 8-K filing by Coherus BioSciences, Inc. (now Coherus Oncology, Inc.) reports a material definitive agreement entered into on February 7, 2017. The filing covers the period from the agreement date through the closing of the transaction on February 13, 2017.
Key Financial Metrics
- Transaction Type: Underwritten public offering of common stock.
- Shares Issued: 5,154,640 shares of common stock.
- Public Offering Price: $24.25 per share.
- Underwriter Purchase Price: $22.795 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 773,196 additional shares.
- Net Proceeds: Approximately $117.1 million (after deducting discounts, commissions, and estimated expenses).
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for operating revenue, profit, or cash flow metrics as this is a transactional report, not a periodic financial statement.
Material Changes
The primary material change is the increase in the company's cash liquidity resulting from the equity offering. The company raised approximately $117.1 million in net proceeds, significantly altering its capital structure and cash position compared to the pre-offering period.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on future operations, or a discussion of risks and contingencies beyond the standard legal disclosures regarding the validity of the securities. The transaction was executed under an effective shelf registration statement (Form S-3, No. 333-208625).
Investor Verification Checklist
- Verify the final number of shares sold, including any exercise of the 773,196 share over-allotment option.
- Confirm the exact amount of net proceeds received after all offering expenses are finalized.
- Review the attached press releases (Exhibits 99.1 and 99.2) for the stated intended use of the raised capital.
- Check subsequent filings for the impact of this capital raise on the company's cash runway and dilution metrics.